Teva Pharmaceutical Industries Limited reported third-quarter sales of USD 4,332 million, up from USD 3,850 million a year ago, but faced a net loss of USD 437 million compared to a net income of USD 69 million last year. For the nine months, sales increased to USD 12,315 million from USD 11,389 million, while the net loss widened to USD 1,422 million from USD 1,022 million. Basic and diluted loss per share from continuing operations were both USD 1.26, compared to USD 0.91 a year ago.